Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia (Q35102485)

6 August 2017

1 reference

title

Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia (English)

1 reference

6 August 2017

0 references

1 reference

John Lauriello

1

1 reference

6 August 2017

Rhoshel Lenroot

series ordinal

2

1 reference

6 August 2017

Juan R Bustillo

series ordinal

3

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Psychiatric Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

26

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

191-211

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Deficit and nondeficit forms of schizophrenia: the concept

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Clinical correlates of the deficit syndrome of schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort.

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Why do schizophrenic patients refuse to take their drugs?

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Effects of psychotherapy in schizophrenia: I. Design and implementation of a controlled study

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Personal therapy: a disorder-relevant psychotherapy for schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, I: Description of Study and Effects on Relapse Rates

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, II: Effects on Adjustment of Patients

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients: I. Outcome.

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Cognitive behavior therapy for persistent auditory hallucinations: From theory to therapy

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

London-east Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. III: Follow-up and economic evaluation at 18 months

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Durability of the effects of cognitive-behavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up.

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Two-year follow-up of cognitive-behavioral therapy and supportive counseling in the treatment of persistent symptoms in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Psychoeducational psychotherapy for schizophrenic patients and their key relatives or care‐givers: results of a 2‐year follow‐up

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Cognitive therapy and recovery from acute psychosis: a controlled trial. I. Impact on psychotic symptoms.

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Compliance therapy in psychotic patients: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of the treatment phase

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Cognitive-behavioral therapy for medication-resistant symptoms

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

A controlled trial of social intervention in the families of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Recent developments in expressed emotion and schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Expressed emotion in staff working with the long-term adult mentally ill

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

The Salford Family Intervention Project: relapse rates of schizophrenia at five and eight years

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Family management in the prevention of exacerbations of schizophrenia: a controlled study.

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

The community management of schizophrenia. A controlled trial of a behavioural intervention with families to reduce relapse

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

A comparison of two levels of family-aided assertive community treatment

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Treatment, expressed emotion and relapse in recent onset schizophrenic disorders

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Family treatment, expressed emotion and relapse in recent onset schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Family management in the prevention of morbidity of schizophrenia: social outcome of a two-year longitudinal study

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Social functioning in schizophrenic patients. I. The effects of expressed emotion and family intervention

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Psychosocial treatment for schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. Environmental-Personal Indicators in the Course of Schizo

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Information processing and attention dysfunctions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Treatment of cognitive dysfunctions and behavioral deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

The effects of neurocognitive remediation on executive processing in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Cognitive therapy with schizophrenic patients: conceptual basis, present state, future directions

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Effects of cognitive treatment in psychiatric rehabilitation.

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Vocational rehabilitation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

An update on supported employment for people with severe mental illness

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Rehabilitative day treatment vs. supported employment: I. Vocational outcomes.

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

A randomized clinical trial of supported employment for inner-city patients with severe mental disorders

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Improving employment outcomes for persons with severe mental illnesses

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Clinical benefits of paid work activity in schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Assertive community treatment: an update of randomized trials

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

A Randomized Trial of Assertive Community Treatment for Homeless Persons With Severe Mental Illness

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

Assertive community treatment and case management for schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

The New Hampshire study of supported employment for people with severe mental illness

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(02)50017-5

7 January 2021

10.1016/S0193-953X(02)00017-5

Identifiers

DOI

1 reference

6 August 2017

1 reference